Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY) Sees Large Decrease in Short Interest

Key Points

• Otsuka Holdings experienced a significant decrease in short interest, dropping by 85.6% from 54,800 shares to just 7,900 shares in September.
• The company's shares rose by 2.3%, trading at $26.69, with a market capitalization of $28.67 billion.
• Zacks Research downgraded Otsuka to a "strong sell" rating, highlighting a general consensus rating of "Sell" among analysts.

Otsuka Holdings Co., Ltd. - Unsponsored ADR (OTCMKTS:OTSKY - Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 15th, there was short interest totaling 7,900 shares, a decrease of 85.6% from the August 31st total of 54,800 shares. Based on an average daily trading volume, of 65,400 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily trading volume, of 65,400 shares, the days-to-cover ratio is currently 0.1 days.

Otsuka Trading Up 2.3%

Shares of OTCMKTS:OTSKY traded up $0.59 on Tuesday, reaching $26.69. The company had a trading volume of 105,815 shares, compared to its average volume of 51,540. The firm has a market capitalization of $28.67 billion and a PE ratio of 0.18. Otsuka has a 52-week low of $21.64 and a 52-week high of $32.41. The firm's 50 day simple moving average is $26.52 and its 200-day simple moving average is $25.10.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised Otsuka to a "strong sell" rating in a research note on Monday, August 11th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Sell".

Otsuka Company Profile

Otsuka Holdings Co, Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. The company develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal system, digestive system, ophthalmology, and diagnostics, as well as intravenous solutions and medical devices.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.